Weekly Endocrinology Research Analysis
This week’s endocrinology literature delivered high-impact, practice-informing results: a head-to-head randomized trial showed tirzepatide produced greater and clinically meaningful weight and waist reductions than semaglutide over 72 weeks. Large-scale human genetics integrated with MR and functional follow-up identified DGKD, SLC34A1, and CYP24A1 as actionable pathways for kidney stone disease, suggesting genotype-guided prevention and druggable targets. A multicenter randomized trial (CHIRACI
Summary
This week’s endocrinology literature delivered high-impact, practice-informing results: a head-to-head randomized trial showed tirzepatide produced greater and clinically meaningful weight and waist reductions than semaglutide over 72 weeks. Large-scale human genetics integrated with MR and functional follow-up identified DGKD, SLC34A1, and CYP24A1 as actionable pathways for kidney stone disease, suggesting genotype-guided prevention and druggable targets. A multicenter randomized trial (CHIRACIC) found that adrenalectomy improves blood‑pressure control and reduces antihypertensive burden in patients with unilateral incidentalomas and mild autonomous cortisol secretion, potentially changing management of MACS-associated hypertension.
Selected Articles
1. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
In a 72-week randomized, open‑label phase 3b trial of adults with obesity without diabetes (n=751), tirzepatide led to significantly greater mean weight loss (−20.2% vs −13.7%) and larger waist circumference reduction (−18.4 cm vs −13.0 cm) than semaglutide. More participants on tirzepatide achieved ≥10–25% weight loss thresholds; gastrointestinal adverse events were common during titration but generally mild–moderate.
Impact: Provides definitive head-to-head evidence positioning tirzepatide as superior to semaglutide for magnitude of weight and central adiposity reduction, shifting the comparative effectiveness landscape for anti‑obesity pharmacotherapy.
Clinical Implications: When maximizing weight and waist reduction is a primary goal in people with obesity without diabetes, tirzepatide should be considered preferentially, with anticipatory counseling about GI tolerability during dose escalation and monitoring for longer-term safety beyond 72 weeks.
Key Findings
- Mean percent weight change at 72 weeks: −20.2% (tirzepatide) vs −13.7% (semaglutide); P<0.001.
- Waist circumference reduction greater with tirzepatide: −18.4 cm vs −13.0 cm; P<0.001.
- Higher proportions achieved ≥10%, ≥15%, ≥20%, and ≥25% weight loss on tirzepatide; GI adverse events were the most common side effects.
2. Genetic variants predisposing to an increased risk of kidney stone disease.
This integrated genomics study identified 79 independent signals at 71 loci for kidney stone disease and used region-specific Mendelian randomization and colocalization to implicate DGKD, SLC34A1, and CYP24A1 in causal calcium/phosphate pathways. Drug‑target MR predicted large relative risk reductions by modulating these pathways, and in vitro assays showed that cinacalcet rescued impaired CaSR signaling caused by DGKD variants, supporting translational potential.
Impact: Integrates population genetics, causal inference, and mechanistic validation to identify common, actionable genetic contributors to nephrolithiasis and nominate druggable pathways, enabling genotype‑informed prevention strategies.
Clinical Implications: Consider incorporating genotyping for high‑risk variants into nephrolithiasis risk assessment and design prospective trials testing pathway‑specific interventions (e.g., calcimimetics, phosphate modulation) for prevention in genetically susceptible individuals.
Key Findings
- Identified 79 independent KSD-associated signals at 71 loci.
- MR implicated increased serum calcium and decreased serum phosphate from three genomic regions as causal for KSD.
- Colocalization placed putative causal noncoding variants near DGKD, SLC34A1, and CYP24A1 (accounting for ~11–19% of cases).
- Drug-target MR and in vitro assays supported pathway druggability; cinacalcet rescued DGKD‑variant CaSR signaling.
3. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial.
CHIRACIC is a multicenter randomized trial showing that adrenalectomy in hypertensive patients with unilateral incidentalomas and MACS resulted in higher rates of home‑measured blood pressure normalization with reduced antihypertensive treatment compared with conservative management (46% vs 15% achieving normotension with medication reduction; adjusted RD 0.34; p=0.0038). ABPM findings supported HBPM results and surgery reduced medication steps with comparable serious adverse event rates.
Impact: Provides the first randomized evidence that targeted adrenal surgery improves hypertension control and reduces medication burden in MACS, resolving an important clinical controversy and informing guidelines.
Clinical Implications: In hypertensive patients with unilateral incidentalomas and confirmed MACS, minimally invasive adrenalectomy should be considered as a management option to reduce antihypertensive therapy and normalize BP, using standardized pre/postoperative HBPM/ABPM protocols.
Key Findings
- Primary endpoint (normotension with reduced antihypertensive therapy) achieved more often after adrenalectomy: 46% vs 15% (adjusted RD 0.34; p=0.0038).
- Surgery group had marked reductions in antihypertensive treatment steps and fewer patients on meds at study end.
- 24‑hour ABPM supported home BP improvements; serious adverse event rates were similar between groups.